IVABRADIN AGAINST BISOPROLOL IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT VENTRICULAL EJECTION FRACTION
In a prospective, randomized trial included 126 patients with chronic heart failure with a left ventricular ejection fraction >50% on a background of arterial hypertension and coronary artery disease, a fixed combination of perindopril/amlodipine was used in all cases, with addition of bisoprolol (n=62) or ivabradine (n=64 ). Assessment of clinical status, exercise tolerance, quality of life, blood level of the N-terminal pro-brain natriuretic peptide, and echocardiography were performed baseline and 12 months after therapy. In contrast to bisoprolol, ivabradine significantly increased the exercise tolerance, improved quality of life, reduced the blood level of the N-terminal pro-brain natriuretic peptide, improved echocardiographic indices of active relaxation and compliance of left ventricle. In comparison with bisoprolol, ivabradine has advantages in the treatment of patients with chronic heart failure with preserved left ventricular ejection fraction on background of arterial hypertension and coronary artery disease.